Table 2. Agents targeting PD-1/PD-L1 in clinical development.
| Company | Agent targeting PD-1 | Agent targeting PD-L1 |
| Bristol-Myers Squibb | BMS-936558/MDX-1106 Nivolumab (fully human IgG4 mAb) | BMS-936559/MDX-1105 (fully human IgG4 mAb) |
| CureTech | CT-011Pidilizumab (humanized IgG1 mAb) | N/A |
| Genentech | N/A | MPDL3280A (IgG1 mAb, Fc modified) |
| MedImmune/AZ | AMP-514 | MEDI4736 (fully human mAb) |
| Merck | MK-3475Pembrolizumab (humanized IgG4 mAb) | N/A |
| EMD Serono | N/A | MSB0010718C |
| Aurigene and Pierre Fabre | AUNP 12 (peptide) | N/A |
PD-1, programmed death 1 receptor; PD-L1, programmed cell death ligand 1; IgG4, immunoglobulin G4; mAb, monoclonal antibody; N/A, not available.